What is the treatment for Hydrogen Small Intestine Bacterial Overgrowth (SIBO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Hydrogen Small Intestinal Bacterial Overgrowth (SIBO) is typically treated with a combination of antibiotics, such as rifaximin, metronidazole, or amoxicillin-clavulanate, along with dietary modifications and supportive measures to reduce symptoms and improve quality of life. The primary goal of treatment is to eradicate the excessive bacteria in the small intestine, reduce malabsorption, and improve nutritional status 1.

Treatment Options

  • Antibiotic therapy: Rifaximin is a commonly used nonabsorbable antibiotic, but other systemically absorbed antibiotics like metronidazole, amoxicillin-clavulanate, and doxycycline may also be effective 1.
  • Dietary modifications: Following a low-fermentable carbohydrate diet, such as the Low FODMAP diet, can help reduce symptoms by limiting bacterial food sources.
  • Supportive measures: Prokinetic agents like low-dose erythromycin or prucalopride may be added to improve intestinal motility and prevent recurrence.

Considerations

  • Addressing the underlying cause of SIBO is crucial for long-term management, whether it's related to structural abnormalities, motility disorders, or other conditions.
  • Recurrence is common, so some patients may require periodic retreatment or a maintenance approach with rotating antibiotics, prokinetics, or herbal antimicrobials like berberine, oregano oil, or allicin.
  • A hydrogen breath test can confirm whether the bacterial overgrowth has been successfully eliminated after treatment 1.

Recent Guidelines

The most recent guidelines suggest that sequential antibiotic therapy is very effective in treating intestinal bacterial overgrowth and reducing malabsorption 1. However, careful patient selection is needed when treating with antibiotics, as they are not US Food and Drug Administration–approved for the indication of SIBO 1.

From the Research

Treatment Options for Hydrogen Small Intestine Bacterial Overgrowth (SIBO)

  • The treatment for Hydrogen SIBO typically involves the use of antibiotics, with rifaximin being a commonly prescribed option 2, 3.
  • Rifaximin has been shown to be effective in providing symptom relief for patients with hydrogen-positive SIBO, with response rates of 47.4% for hydrogen positivity alone and 80% for both hydrogen and methane positivity 2.
  • Other antibiotics, such as metronidazole, may also be used to treat SIBO, although rifaximin has been shown to have a higher SIBO decontamination rate and better tolerability 3.
  • Herbal therapy has also been found to be equivalent to rifaximin for the treatment of SIBO, with a remission rate of 46% compared to 34% for rifaximin users 4.
  • Nonantibiotic-based treatment strategies, such as probiotics, diet manipulation, and prokinetic agents, are also being explored as potential therapeutic options for SIBO 5.

Antibiotic Therapy for SIBO

  • Rifaximin is a poorly absorbed antibiotic that has been shown to be effective in treating SIBO, particularly for patients with hydrogen-positive breath tests 2, 3.
  • Metronidazole is another antibiotic that may be used to treat SIBO, although it has been shown to have a lower SIBO decontamination rate and more adverse effects compared to rifaximin 3.
  • The use of antibiotics for SIBO treatment is generally empiric, and there is a limited database to guide the clinician in developing antibiotic strategies 6.

Emerging Therapies for SIBO

  • Herbal therapy has been found to be a potential alternative to antibiotic therapy for SIBO, with similar efficacy and fewer adverse effects 4.
  • Probiotics, diet manipulation, and prokinetic agents are also being explored as potential therapeutic options for SIBO, although more research is needed to confirm their effectiveness 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Preferential usage of rifaximin for the treatment of hydrogen-positive smallintestinal bacterial overgrowth.

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru, 2019

Research

Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.

European review for medical and pharmacological sciences, 2009

Research

Small intestinal bacterial overgrowth: current update.

Current opinion in gastroenterology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.